## Drug of Choice for Active Trachoma **Key Point:** Azithromycin is the WHO-recommended first-line agent for active trachoma (TF and TI stages) caused by *Chlamydia trachomatis*. ### Mechanism & Rationale Azithromycin is a macrolide antibiotic that: - Penetrates intracellular chlamydial organisms effectively - Achieves high ocular and systemic concentrations - Can be given as a single-dose oral regimen (20 mg/kg once) or short course - Eradicates the pathogen and halts disease progression ### Comparison with Alternatives | Agent | Route | Efficacy | Limitations | Role | |-------|-------|----------|-------------|------| | **Azithromycin** | Oral (single dose) | ~95% cure | None significant | **First-line** | | Tetracycline ointment | Topical (6 weeks) | ~80% cure | Long duration, poor compliance, risk of resistance | Alternative if oral unavailable | | Ciprofloxacin | Topical/oral | Moderate | Less effective than macrolides; fluoroquinolone resistance emerging | Not preferred | | Gentamicin | Topical | Poor | Gram-negative coverage only; ineffective against intracellular chlamydia | Not used | **High-Yield:** WHO/SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) recommends **single-dose oral azithromycin** as the antibiotic pillar for elimination of trachoma in endemic regions. **Clinical Pearl:** A single oral dose of azithromycin (20 mg/kg) is superior to 6 weeks of tetracycline eye ointment in terms of compliance, systemic eradication, and prevention of reinfection in household contacts. **Mnemonic:** **AZITH** = **A**ntibacterial **Z**oonotic **I**nfection **T**reatment **H**igh-efficacy (macrolide for chlamydial trachoma).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.